{"url_path":"/sec/apls/8-k/2026-05-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","accession_number":"0001193125-26-222923","cik":"0001492422","ticker":"APLS","issuer_name":"Apellis Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","primary_entity_key":"0001492422","primary_entity_name":"Apellis Pharmaceuticals, Inc."},"word_count":147,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn the Note Effective Date, the Company issued a notice (the “Notice”) announcing that the consummation of the Merger constituted a Merger Event under the Indenture, and that each of the Merger, the Offer and the delisting of the shares of Shares from Nasdaq constituted a Fundamental Change and Make-Whole Fundamental Change (each as defined in the Indenture). A copy of the Notice is filed as Exhibit 99.1 hereto and is incorporated herein by reference.\n\nThe information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}